2020
Immuron's stock pulls back but still nearly doubles after stock offering
21 July 2020
Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA
9 June 2020
21 July 2020
9 June 2020
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.
The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.
E-commerce software by Neto